{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T03:42:39Z","timestamp":1776310959646,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000033","name":"Institute of Musculoskeletal Health and Arthritis","doi-asserted-by":"publisher","award":["FRN153298"],"award-info":[{"award-number":["FRN153298"]}],"id":[{"id":"10.13039\/501100000033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Identification of the optimal treatment for a given patient is of paramount importance. This is of particular relevance in osteoarthritis (OA) because of the high prevalence of the disease, extensive heterogeneity of the disease, and need for long-term treatment. The aim of the study was to examine whether serum lysophosphatidylcholines (lysoPCs) to phosphatidylcholines (PCs) ratio can predict clinical response to licofelone and naproxen treatments in symptomatic knee OA patients.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>One hundred fifty-eight OA patients who completed the study according to protocol (ATP) of a previous 24-month clinical trial cohort comparing the effect of licofelone vs. naproxen in symptomatic knee OA patients were included. Symptomatic responses to either treatments were classified according to the OARSI-OMERACT criteria based on the WOMAC scores at 24\u00a0months. Total concentrations of PCs and lysoPCs were measured in the serum samples collected before the initiation of the treatments, and the lysoPCs to PCs ratio was calculated. Student\u2019s <jats:italic>t<\/jats:italic> test was utilized to compare the difference in the ratio of lysoPCs to PCs between the symptomatic responders and non-responders. Logistic regression was utilized to adjust for the potential confounders. Receiver operating characteristic (ROC) analysis was performed to identify the optimal cutoff of the ratio for prediction.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Data showed that 61.4% of the patients symptomatically responded to licofelone and naproxen and 38.6% were deemed as therapeutic failures (non-responders). There was no difference in responders between licofelone and naproxen (<jats:italic>p<\/jats:italic>\u2009=\u20090.87). Responders had a significantly higher lysoPCs to PCs ratio than non-responders (0.097\u2009\u00b1\u20090.003 vs. 0.085\u2009\u00b1\u20090.003; <jats:italic>p<\/jats:italic>\u2009=\u20090.006). Patients with a ratio greater than the optimal cutoff of 0.088 had 2.93 times more likely to respond to licofelone and naproxen (<jats:italic>p<\/jats:italic>\u2009=\u20090.002).<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Serum lysoPCs to PCs ratio is a marker for response to licofelone and naproxen and may aid in the personalized treatment to knee OA.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-019-2006-8","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T15:03:40Z","timestamp":1573052620000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Serum lysophosphatidylcholines to phosphatidylcholines ratio is associated with symptomatic responders to symptomatic drugs in knee osteoarthritis patients"],"prefix":"10.1186","volume":"21","author":[{"given":"Guangju","family":"Zhai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Pelletier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward W.","family":"Randell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanne","family":"Martel-Pelletier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"key":"2006_CR1","unstructured":"WHO Scientific Group. The burden of musculoskeletal conditions at the start of the new millennium: Report of a WHO Scientific Group. In. Geneva: World Health Organisation; 2003."},{"issue":"9859","key":"2006_CR2","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","volume":"380","author":"T Vos","year":"2012","unstructured":"Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163\u201396.","journal-title":"Lancet"},{"issue":"3","key":"2006_CR3","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.semarthrit.2013.07.003","volume":"43","author":"M Hiligsmann","year":"2013","unstructured":"Hiligsmann M, Cooper C, Arden N, Boers M, Branco JC, Luisa Brandi M, Bruyere O, Guillemin F, Hochberg MC, Hunter DJ, et al. Health economics in the field of osteoarthritis: an expert\u2019s consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2013;43(3):303\u201313.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"2006_CR4","doi-asserted-by":"publisher","first-page":"R39","DOI":"10.1186\/ar2394","volume":"10","author":"RA Moore","year":"2008","unstructured":"Moore RA, Moore OA, Derry S, McQuay HJ. Numbers needed to treat calculated from responder rates give a better indication of efficacy in osteoarthritis trials than mean pain scores. Arthritis Res Ther. 2008;10(2):R39.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"2006_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2174\/156802607779941305","volume":"7","author":"SK Kulkarni","year":"2007","unstructured":"Kulkarni SK, Singh VP. Licofelone--a novel analgesic and anti-inflammatory agent. Curr Top Med Chem. 2007;7(3):251\u201363.","journal-title":"Curr Top Med Chem"},{"key":"2006_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-230X-4-4","volume":"4","author":"AJ Smolka","year":"2004","unstructured":"Smolka AJ, Goldenring JR, Gupta S, Hammond CE. Inhibition of gastric H,K-ATPase activity and gastric epithelial cell IL-8 secretion by the pyrrolizine derivative ML 3000. BMC Gastroenterol. 2004;4:4.","journal-title":"BMC Gastroenterol"},{"issue":"9","key":"2006_CR7","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1093\/rheumatology\/kew207","volume":"55","author":"W Zhang","year":"2016","unstructured":"Zhang W, Sun G, Aitken D, Likhodii S, Liu M, Martin G, Furey A, Randell E, Rahman P, Jones G, et al. Lysophosphatidylcholines to phosphatidylcholines ratio predicts advanced knee osteoarthritis. Rheumatology (Oxford). 2016;55(9):1566\u201374.","journal-title":"Rheumatology (Oxford)"},{"key":"2006_CR8","volume-title":"Activation of the phosphatidylcholine to lysophosphatidylcholine pathway is associated with osteoarthritis knee cartilage volume loss over time scientific reports","author":"G Zhai","year":"2019","unstructured":"Zhai G, Pelletier JP, Liu M, Aitken D, Randell E, Rahman P, Jones G, Martel-Pelletier J: Activation of the phosphatidylcholine to lysophosphatidylcholine pathway is associated with osteoarthritis knee cartilage volume loss over time scientific reports 2019, In press."},{"issue":"2","key":"2006_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.bbalip.2011.11.006","volume":"1821","author":"AM Astudillo","year":"2012","unstructured":"Astudillo AM, Balgoma D, Balboa MA, Balsinde J. Dynamics of arachidonic acid mobilization by inflammatory cells. Biochim Biophys Acta. 2012;1821(2):249\u201356.","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"2006_CR10","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1136\/ard.2008.088732","volume":"68","author":"JP Raynauld","year":"2009","unstructured":"Raynauld JP, Martel-Pelletier J, Bias P, Laufer S, Haraoui B, Choquette D, Beaulieu AD, Abram F, Dorais M, Vignon E, et al. Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. Ann Rheum Dis. 2009;68(6):938\u201347.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2006_CR11","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/rheumatology\/kev408","volume":"55","author":"J Martel-Pelletier","year":"2016","unstructured":"Martel-Pelletier J, Raynauld JP, Dorais M, Abram F, Pelletier JP. The levels of the adipokines adipsin and leptin are associated with knee osteoarthritis progression as assessed by MRI and incidence of total knee replacement in symptomatic osteoarthritis patients: a post hoc analysis. Rheumatology (Oxford). 2016;55(4):680\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"2006_CR12","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1136\/ard.2009.122002","volume":"69","author":"JP Pelletier","year":"2010","unstructured":"Pelletier JP, Raynauld JP, Caron J, Mineau F, Abram F, Dorais M, Haraoui B, Choquette D, Martel-Pelletier J. Decrease in serum level of matrix metalloproteinases is predictive of the disease-modifying effect of osteoarthritis drugs assessed by quantitative MRI in patients with knee osteoarthritis. Ann Rheum Dis. 2010;69(12):2095\u2013101.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2006_CR13","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/art.1780290816","volume":"29","author":"R Altman","year":"1986","unstructured":"Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986;29(8):1039\u201349.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2006_CR14","first-page":"1648","volume":"30","author":"T Pham","year":"2003","unstructured":"Pham T, Van Der Heijde D, Lassere M, Altman RD, Anderson JJ, Bellamy N, Hochberg M, Simon L, Strand V, Woodworth T, et al. Outcome variables for osteoarthritis clinical trials: the OMERACT-OARSI set of responder criteria. J Rheumatol. 2003;30(7):1648\u201354.","journal-title":"J Rheumatol"},{"issue":"10","key":"2006_CR15","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.clinbiochem.2005.06.006","volume":"38","author":"B Fuchs","year":"2005","unstructured":"Fuchs B, Schiller J, Wagner U, Hantzschel H, Arnold K. The phosphatidylcholine\/lysophosphatidylcholine ratio in human plasma is an indicator of the severity of rheumatoid arthritis: investigations by 31P NMR and MALDI-TOF MS. Clin Biochem. 2005;38(10):925\u201333.","journal-title":"Clin Biochem"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-2006-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-019-2006-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-2006-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:47:42Z","timestamp":1604537262000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-019-2006-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,6]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2006"],"URL":"https:\/\/doi.org\/10.1186\/s13075-019-2006-8","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,6]]},"assertion":[{"value":"25 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original study protocol was approved by a central review board (IRB Institutional Review Board Services, Toronto, ON, Canada) and the institutional review board of the Centre hospitalier de l\u2019Universit\u00e9 Sherbrooke (Sherbrooke, QC, Canada). The original trial was conducted in compliance with the ethical principles that have their origin in the Declaration of Helsinki (2000) and are consistent with the \u201cGood Clinical Practice\u201d ICH Tripartite Guideline (January 1997) and the applicable laws and regulations of Canada, whichever afforded the greater protection to the individual. Ethical approval for this post hoc study was obtained with the original study; thus, further approval was not required. All patients provided informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"224"}}